Deepfake doctors and counterfeit injectables erode patient safety
1. Deepfake clinicians and AI-shaped wellness content are blurring the line between medical advice and marketing in ways that patients...
Dermatology
Drug-related pressure ulcers may be characterised by medication-related characteristics such as polypharmacy and medication changes rather than baseline immobility
1. Approximately one in nine hospitalised patients with pressure ulcers met criteria for definite drug-related pressure ulcers (DRPU), characterised by...
AI bandage cuts wound healing time in new study
1. On September 24, 2025, researchers reported that an AI bandage called a-Heal sped wound healing by 25 percent in...
Artificial intelligence matches dermatologists in melanoma diagnosis
1. Artificial intelligence triage for melanoma shows more than 90 percent sensitivity and is now in trials within the National...
Microneedling with tranexamic acid may improve outcomes for patients with melasma
1. Among patients with melasma, microneedling with tranexamic acid was superior to microneedling with metformin or the control treatment in...
Remibrutinib alleviates symptoms in chronic spontaneous urticaria resistant to H1-antihistamines
1. In this randomized controlled trial, among patients with chronic spontaneous urticaria who continue to have symptoms while on second-generation...
Coronary CT-angiography-guided management improves outcomes in patients with stable chest pain
1. Composite of coronary heart disease death and non-fatal myocardial infarction was less frequent in the CCTA group compared to...
Dazukibart is effective in reducing disease activity in adults with refractory dermatomyositis
1. CDASI-A score at 12 weeks was significantly lower in dazukibart 600 mg versus placebo, suggesting reduced morbidity. 2. Treatment-related...
Neoadjuvant ipilimumab plus nivolumab improves event-free survival in stage III melanoma
1. In this randomized controlled trial, two cycles of neoadjuvant ipilimumab plus nivolumab resulted in longer event-free survival than adjuvant...
Adjuvant dabrafenib and trametinib improve survival in stage III melanoma
1. After almost 10 years of follow-up, adjuvant dabrafenib and trametinib improved relapse-free and metastasis-free survival compared to placebo in...
